IL10 and Parkinson disease: One-week rifaximin treatment caused an increased trend of serum anti-inflammatory cytokine, IL-10 increase (baseline:15.88 ± 8.60, 6-month post-rifaximin: 26.82 ± 25.32 pg/mL, p = 0.06) without significant change in the rest of the serum cytokine profile of the patients with PD (Table 2).